Elizabeta A. Rojas, Sara Cristóbal-Vargas, David Becerro-Recio, Cristina De Ramón, Myriam Cuadrado, Isabel Isidro, Irena Misiewicz-Krzeminska, Joaquín Martínez-López, Albert Oriol, Laura Rosiñol, Juan José Lahuerta, Jesús F. San Miguel, María Victoria Mateos, Luis A. Corchete, Norma C. Gutiérrez
{"title":"Study of post-translational modifications of p53 in multiple myeloma","authors":"Elizabeta A. Rojas, Sara Cristóbal-Vargas, David Becerro-Recio, Cristina De Ramón, Myriam Cuadrado, Isabel Isidro, Irena Misiewicz-Krzeminska, Joaquín Martínez-López, Albert Oriol, Laura Rosiñol, Juan José Lahuerta, Jesús F. San Miguel, María Victoria Mateos, Luis A. Corchete, Norma C. Gutiérrez","doi":"10.1038/s41408-026-01568-x","DOIUrl":"https://doi.org/10.1038/s41408-026-01568-x","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"47 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148459553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lauren R Teras,Mariah Landry,James M Hodge,Parichoy Pal Choudhury,Brenda M Birmann,Wendy Cozen,Jonathan N Hofmann,Rima Jeske,Mark P Purdue,James R Cerhan,Loïc Le Marchand,Aisha Babi,Alpa V Patel,Tim Waterboer
{"title":"Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts.","authors":"Lauren R Teras,Mariah Landry,James M Hodge,Parichoy Pal Choudhury,Brenda M Birmann,Wendy Cozen,Jonathan N Hofmann,Rima Jeske,Mark P Purdue,James R Cerhan,Loïc Le Marchand,Aisha Babi,Alpa V Patel,Tim Waterboer","doi":"10.1038/s41408-026-01520-z","DOIUrl":"https://doi.org/10.1038/s41408-026-01520-z","url":null,"abstract":"Non-Hodgkin lymphomas (NHLs) are among the most common cancers in the US, yet their etiology is mostly unknown. Epstein-Barr virus (EBV) is a known driver of rare NHLs, but its role in common subtypes is unclear. We evaluated associations between antibodies to 16 EBV antigens, including 12 emerging markers (anti-: BARF1, BBRF1, BFRF1, BGLF2, BHRF1, BORF1, BPLF1, BRLF1, BXLF1, LF2, LMP1, VCAp40) and NHL risk in prediagnostic blood samples from 2134 case-control sets from 4 prospective cohort studies. Conditional logistic regression estimated odds ratios (ORs) and 95% confidence intervals (CIs). Associations across multiple antibodies were summarized using a β‑weighted score (EBVAb score). Eight markers were positively associated with NHL risk. Anti-LMP1 was associated with diffuse large B-cell lymphoma (DLBCL; OR = 2.83, 95% CI: 1.12-7.19) only. Six lytic markers (anti-: BGLF2, VCAp40, BFRF1, BARF1, BHRF1, BXLF1) were associated with a 2-3 times higher risk of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Lytic marker associations for DLBCL and follicular lymphoma (FL) were weaker, with exceptions: anti-BXLF1 and DLBCL: OR = 2.25, 95% CI: 1.33-3.81; anti-BHRF1 and FL: OR = 2.75, 95% CI: 1.22-6.18. Anti-EBV scores > 0 were associated with ~50% higher NHL risk, strongest for CLL/SLL (Tertile 3: OR = 2.43, 95% CI: 1.30-4.55). Select EBV antibodies may serve as markers of common NHL risk.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"1 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148451542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Utkarsh Goel, Catalin Dragomirescu, Roy Chedid, Diana Basali, Louis Williams, Sandra Mazzoni, Jason Valent, Shahzad Raza, Faiz Anwer, Jack Khouri
{"title":"Response kinetics and depth of response after idecabtagene vicleucel in relapsed/refractory multiple myeloma","authors":"Utkarsh Goel, Catalin Dragomirescu, Roy Chedid, Diana Basali, Louis Williams, Sandra Mazzoni, Jason Valent, Shahzad Raza, Faiz Anwer, Jack Khouri","doi":"10.1038/s41408-026-01582-z","DOIUrl":"https://doi.org/10.1038/s41408-026-01582-z","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"32 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148459560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xueping Wan,Ting Du,Teng Fang,Minxing Wang,Arghya Ray,Kenneth Wen,Md Abu Musa,Filip Garbicz,Ruben D Carrasco,Anil A Samur,Mariateresa Fulciniti,Srikanth Talluri,Yan Song,Nikhil C Munshi,Kenneth C Anderson
{"title":"The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myeloma.","authors":"Xueping Wan,Ting Du,Teng Fang,Minxing Wang,Arghya Ray,Kenneth Wen,Md Abu Musa,Filip Garbicz,Ruben D Carrasco,Anil A Samur,Mariateresa Fulciniti,Srikanth Talluri,Yan Song,Nikhil C Munshi,Kenneth C Anderson","doi":"10.1038/s41408-026-01574-z","DOIUrl":"https://doi.org/10.1038/s41408-026-01574-z","url":null,"abstract":"Multiple myeloma (MM) is a plasma cell malignancy characterized by genomic instability and a high dependency on proteasome activity. Accordingly, DNA-damaging agents and proteasome inhibitors (PIs) are frontline therapies; however, therapeutic resistance inevitably develops. RAD23A, a dual-function protein involved in nucleotide excision repair and proteasome-mediated protein degradation, is highly expressed in MM and is associated with poor patient survival. Here, we demonstrate that depletion of RAD23A exerts potent anti-MM activity both in vitro and in vivo. Inducible CRISPR/Cas9 knockout (iKO) or shRNA-mediated knockdown of RAD23A in MM cell lines, including PI-resistant models, markedly suppressed cell proliferation. RAD23A loss impaired DNA repair capacity, triggered activation of the stress-associated eIF2α-ATF4 axis and promoted caspase-dependent apoptosis. Quantitative proteomic profiling of RAD23A-iKO cells confirmed upregulation of apoptotic and stress-response pathways, accompanied by downregulation of DNA repair and deubiquitination pathways. In an MM xenograft model, RAD23A depletion significantly reduced tumor growth and prolonged survival. Collectively, these findings identify RAD23A as a critical survival factor in MM and highlight its potential as a novel therapeutic target.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"37 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148451435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yun Kang,Qiaolin Liu,Lin Liu,Wei Xie,Chunyan Sun,Heng Mei
{"title":"Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis.","authors":"Yun Kang,Qiaolin Liu,Lin Liu,Wei Xie,Chunyan Sun,Heng Mei","doi":"10.1038/s41408-026-01564-1","DOIUrl":"https://doi.org/10.1038/s41408-026-01564-1","url":null,"abstract":"Relapse following B-cell maturation antigen (BCMA)-directed therapies represents a critical challenge in relapsed/refractory multiple myeloma (R/R MM). We performed a systematic review and meta-analysis of 34 studies (n = 1280) published between 2020 and 2025 to evaluate salvage CAR-T versus engineered antibody therapies post-BCMA exposure. The pooled overall response rate (ORR) was 60%. CAR-T therapy achieved significantly superior ORR compared to antibody-based approaches (77% vs 52%; p < 0.0001), with comparable complete response rates. While incidences of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome were similar, grade ≥3 cytopenias were more frequent with CAR-T. Notably, GPRC5D-targeted CAR-T yielded higher ORRs than BCMA-targeted constructs (86% vs 66%; p = 0.0006). Furthermore, patients with prior exposure to BCMA bispecific antibodies exhibited lower response rates compared to those with prior CAR-T exposure (71% vs 86%; p = 0.0404). In addition, studies with a median interval of ≥10 months demonstrated significantly higher ORRs than those with <10 months (70% vs 50%; p = 0.0146). In conclusion, GPRC5D CAR-T demonstrates superior efficacy to engineered antibodies in the post-BCMA setting. These findings support prioritising earlier CAR-T use and underscore the importance of antigen selection in optimising treatment sequencing.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"31 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148441096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Stephen P. Martindale, Roberta Santos Azevedo, Drew A. Harrison, Bethany Tesar, Winnie Nguy, Miranda Stiegler, Valeria Ferre, Vanessa Rai, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Stacey M. Fernandes, John-Hanson Machado, Binu Kandathilparambil Sasi, Aishath Naeem, Christopher J. Ott, Jennifer R. Brown
{"title":"Preclinical and clinical efficacy of the HDAC6 inhibitor ricolinostat in combination with BCR pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia","authors":"Stephen P. Martindale, Roberta Santos Azevedo, Drew A. Harrison, Bethany Tesar, Winnie Nguy, Miranda Stiegler, Valeria Ferre, Vanessa Rai, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Stacey M. Fernandes, John-Hanson Machado, Binu Kandathilparambil Sasi, Aishath Naeem, Christopher J. Ott, Jennifer R. Brown","doi":"10.1038/s41408-026-01559-y","DOIUrl":"https://doi.org/10.1038/s41408-026-01559-y","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"42 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148432036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma.","authors":"Jiadai Xu,Jing Li,Yuhong Ren,Luya Cheng,Zhixiang Cheng,Jingli Zhuang,Yang Ke,Shiyang Gu,Yian Zhang,Feifei Chen,Rupan Gao,Panpan Li,Yaqin Xiong,Peng Liu","doi":"10.1038/s41408-026-01575-y","DOIUrl":"https://doi.org/10.1038/s41408-026-01575-y","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"34 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148416610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Giuseppe G Loscocco,Fnu Aperna,Moazah Iftikhar,Priyansh Faldu,Masooma S Rana,Amritpal Singh,Tiziano Barbui,Paola Guglielmelli,Alessandro M Vannucchi,Animesh Pardanani,Naseema Gangat,Ayalew Tefferi
{"title":"Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia.","authors":"Giuseppe G Loscocco,Fnu Aperna,Moazah Iftikhar,Priyansh Faldu,Masooma S Rana,Amritpal Singh,Tiziano Barbui,Paola Guglielmelli,Alessandro M Vannucchi,Animesh Pardanani,Naseema Gangat,Ayalew Tefferi","doi":"10.1038/s41408-026-01560-5","DOIUrl":"https://doi.org/10.1038/s41408-026-01560-5","url":null,"abstract":"Patients with myeloproliferative neoplasms (MPN), including polycythemia vera (PV) and essential thrombocythemia (ET), have an increased risk of second cancers (SC), although determinants of risk remain incompletely defined. We retrospectively analyzed 1968 consecutive patients with PV or ET (median follow-up 11.2 years) to identify predictors of SC. Cumulative incidence functions were estimated using competing-risk methodology, and predictors were assessed using Fine-Gray regression. During follow-up, SC occurred in 404 patients (20%), with non-melanoma skin cancer (NMSC) representing the most frequent subtype. In multivariable models including all cancer types, prior cancer (sHR 2.02, p < 0.001), older age (per 10 years: sHR 1.20, p < 0.001), male sex (sHR 1.39, p = 0.002), and hyperlipidemia (sHR 1.41, p = 0.003) independently predicted SC. After excluding NMSC, prior cancer remained associated with SC risk (sHR 1.48, p = 0.048). Notably, prior NMSC strongly predicted subsequent NMSC (sHR 6.48, p < 0.001), followed by prior non-NMSC cancer (sHR 2.11, p < 0.001), age (sHR 1.29, p < 0.001), and male sex (sHR 1.43, p = 0.018). TET2 mutations showed a borderline association with NMSC risk (sHR 1.73, p = 0.055), while hydroxyurea was not associated with SC, with a non-significant trend toward increased NMSC risk (sHR 1.82, p = 0.110). These findings support risk-adapted cancer surveillance in PV and ET, with particular emphasis on regular dermatologic monitoring.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"221 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148416609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
